Abstract:Therapeutic drug monitoring (TDM) receives growing interest in different psychiatric clinical settings (emergency, inpatient, and outpatient services). Despite its usefulness, TDM remains underemployed in mental health. This is partly due to the need for evidence about the relationship between drug serum concentration and efficacy and tolerability, both in the general population and even more in subpopulations with atypical pharmacokinetics. This work aims at reviewing the scientific literature published after 2017, when the most recent guidelines about the use of TDM in mental health were written. We found 164 pertinent records that we included in the review. Some promising studies highlighted the possibility of correlating early drug serum concentration and clinical efficacy and safety, especially for antipsychotics, potentially enabling clinicians to make decisions on early laboratory findings and not proceeding by trial and error. About populations with pharmacokinetic peculiarities, the latest studies confirmed very common alterations in drug blood levels in pregnant women, generally with a progressive decrease over pregnancy and a very relevant dose-adjusted concentration increase in the elderly. For adolescents also, several drugs result in having different dose-related concentration values compared to adults. These findings stress the recommendation to use TDM in these populations to ensure a safe and effective treatment. Moreover, the integration of TDM with pharmacogenetic analyses may allow clinicians to adopt precise treatments, addressing therapy on an individual pharmacometabolic basis. Mini-invasive TDM procedures that may be easily performed at home or in a point-of-care are very promising and may represent a turning point toward an extensive real-world TDM application. Although the highlighted recent evidence, research efforts have to be carried on: further studies, especially prospective and fixed-dose, are needed to replicate present findings and provide clearer knowledge on relationships between dose, serum concentration, and efficacy/safety.

Therapeutic Drug Monitoring and Pharmacokinetics-Based Individualization of Drug Therapy

Emerging therapeutic drug monitoring technologies: considerations and opportunities in precision medicine

Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau"

[Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry]

Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes

Utility, promise, and limitations of liquid chromatography‐mass spectrometry‐based therapeutic drug monitoring in precision medicine

Establishing and Extending the Use of Therapeutic Drug Monitoring in Neuropsychopharmacology

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib

Overview and Progress of Therapeutic Drug Monitoring

Principles of therapeutic drug monitoring.

Overview of therapeutic drug monitoring and clinical practice

Understanding Therapeutic drug monitoring (TDM) at a glance

Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place

Therapeutic drug monitoring in kidney and liver transplantation: current advances and future directions

Current Status of Therapeutic Drug Monitoring in Mental Health Treatment: A Review

Therapeutic drug monitoring (TDM) in real-time: a need for the present future

Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy

Therapeutic drug monitoring in tuberculosis

Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Therapeutic drug monitoring of oral targeted antineoplastic drugs